Compounds > flavokawain C
Page last updated: 2024-12-11

flavokawain C

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

flavokawain C: antineoplastic from roots of Kava (Piper methysticum Forst); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6293081
CHEMBL ID251958
CHEBI ID157718
SCHEMBL ID144230

Synonyms (35)

Synonym
AQ-358/42003063
1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one
flavokawain c
56798-34-6
flavokawin
flavokawin c
LMPK12120320
CHEMBL251958
(e)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
CHEBI:157718
1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
37308-75-1
2',4-dihydroxy-4',6'-dimethoxychalcone
flavokavain c
SCHEMBL144230
AKOS024306997
flavokawainc
AC-34389
flavokavin c
2-propen-1-one, 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)-
UXUFMIJZNYXWDX-VMPITWQZSA-N
4,2'-dihydroxy-4',6'-dimethoxychalcone
2-propen-1-one, 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)-, (e)-
4,2'-dihydroxy-4',6'-dimethylchalcone
mfcd00016489
Q5458168
MS-24327
DTXSID60958437
2,4-dihydroxy-4,6-dimethoxychalcone
5le8ktr6g2 ,
4-hydroxyflavokawain b
2-propen-1-one, 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)-, (2e)-
(2e)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one
(e)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (flavokawain c)
2',4-dihydroxy-4',6'-dimethoxy-trans-chalcone

Research Excerpts

Overview

Flavokawain C (FKC) is a naturally occurring chalcone which can be found in Kava (Piper methysticum Forst) root.

ExcerptReferenceRelevance
"Flavokawain C (FKC) is a naturally occurring chalcone which can be found in Kava (Piper methysticum Forst) root. "( Flavokawain C Inhibits Cell Cycle and Promotes Apoptosis, Associated with Endoplasmic Reticulum Stress and Regulation of MAPKs and Akt Signaling Pathways in HCT 116 Human Colon Carcinoma Cells.
Abd Malek, SN; Karsani, SA; Phang, CW; Sethi, G, 2016)		3.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
chalconesA ketone that is 1,3-diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar, and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)8.00000.00011.97318.0000AID1142307
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)IC50 (µMol)8.00000.00011.80888.0000AID1142307
Transcription factor p65Homo sapiens (human)IC50 (µMol)8.00000.00011.89818.8000AID1142307
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
follicular dendritic cell differentiationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
germinal center formationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
extracellular matrix organizationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to lipopolysaccharideNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
rhythmic processNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
spleen developmentNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
protein bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytosolNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
chromatinNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
Bcl3/NF-kappaB2 complexNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1737236Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 10 uM measured after 24 hrs by Griess reagent based assay relative to control2020European journal of medicinal chemistry, May-01, Volume: 193Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation.
AID1190838Inhibition of mushroom tyrosinase using L-tyrosine as substrate after 20 mins by microplate reader2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Flavokawains B and C, melanogenesis inhibitors, isolated from the root of Piper methysticum and synthesis of analogs.
AID311568Cytotoxicity against human PANC1 cells assessed as cell viability2007Journal of natural products, Oct, Volume: 70, Issue:10
Bioactive secondary metabolites from Boesenbergia pandurata of Myanmar and their preferential cytotoxicity against human pancreatic cancer PANC-1 cell line in nutrient-deprived medium.
AID1100871Antifeedant activity against Spodoptera litura in compound treated cork borer from fresh sweet potato leaves by Choice Leaf-Disk Bioassay2000Journal of agricultural and food chemistry, May, Volume: 48, Issue:5
Insect antifeedant flavonoids from Gnaphalium affine D. Don.
AID551964Cytotoxicity against mouse NIH/3T3 cells assessed as cell viability after 8 hrs2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies.
AID1190839Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Flavokawains B and C, melanogenesis inhibitors, isolated from the root of Piper methysticum and synthesis of analogs.
AID447711Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity.
AID551962Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies.
AID1142307Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Bis(4-hydroxy-2H-chromen-2-one): synthesis and effects on leukemic cell lines proliferation and NF-κB regulation.
AID447716Hepatotoxicity against mouse Hepa-1c1c7 cells after 48 hrs by celltiter blue assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity.
AID340661Cytotoxicity against human HeLa cells by MTT assay after 72 hrs2008Journal of natural products, Jul, Volume: 71, Issue:7
Synthesis, cytotoxicity, and antioxidative activity of minor prenylated chalcones from Humulus lupulus.
AID340662Antioxidant activity assessed as trolox equivalents at 0.1 to 1 uM by ORAC-fluorescein assay2008Journal of natural products, Jul, Volume: 71, Issue:7
Synthesis, cytotoxicity, and antioxidative activity of minor prenylated chalcones from Humulus lupulus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's5 (41.67)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.48 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
kojic acid
[no description available]		2.11104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
beta-lapachone
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.		2.110benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
phloretin
[no description available]		2.110dihydrochalconesantineoplastic agent;
plant metabolite
sanguinarine
benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.		2.110alkaloid antibiotic;
benzophenanthridine alkaloid;
botanical anti-fungal agent
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		210organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
methyl gallate
methyl gallate: has both immunosuppressive and phytogenic antineoplastic activities; isolated from Acer saccharinum. methyl 3,4,5-trihydroxybenzoate : A gallate ester obtained by the formal condensation of gallic acid with methanol. It exhibits anti-oxidant, anti-tumor, anti-microbial and anti-inflammatory properties.		2.610gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
pregnanolone
Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.		2.6103-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid		human metabolite;
intravenous anaesthetic;
sedative
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0310taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
arctigenin
arctigenin: precursor to catechols; in many plants		2.0310lignan
pinocembrin
pinocembrin : A dihydroxyflavanone in which the two hydroxy groups are located at positions 5 and 7. A natural product found in Piper sarmentosum and Cryptocarya chartacea.		2.0310(2S)-flavan-4-one;
dihydroxyflavanone		antineoplastic agent;
antioxidant;
metabolite;
neuroprotective agent;
vasodilator agent
tangeretin
tangeretin: structure given in first source; from citrus plants; inhibits invasion of MO4 mouse cells into embryonic chick heart in vitro. tangeretin : A pentamethoxyflavone flavone with methoxy groups at positions 4', 5, 6 , 7 and 8.. pentamethoxyflavone : A methoxyflavone that is flavone substituted by a five methoxy groups.		210pentamethoxyflavoneantineoplastic agent;
plant metabolite
pinostrobin
[no description available]		2.0310monohydroxyflavanone;
monomethoxyflavanone		antidote;
plant metabolite
7,8-dihydromethysticin
[no description available]		2.05102-pyranones;
aromatic ether
altersolanol a
altersolanol A: isolated from fermentation product of fungus Alternaria porri(Ellis) Ciferri;RN given refers to (1R-(1alpha,2beta,3beta,4alpha))-isomer; structure given in first source		2.110pentahydroxyanthraquinone
gardenin b
gardenin B: has antineoplastic activity; structure in first source. gardenin B : A tetramethoxyflavone that is tangeretin in which the methoxy group at position 5 has been replaced by a hydroxy group.		210monohydroxyflavone;
tetramethoxyflavone		plant metabolite
ferulic acid
ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.		2.0410ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
4-hydroxypanduratin a
4-hydroxypanduratin A: putative skin-whitening agent; isolated from Kaempferia pandurata; structure in first source		2.0310
chalcone
trans-chalcone : The trans-isomer of chalcone.		2.0610chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
isoliquiritigenin
[no description available]		2.4820chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
xanthohumol
xanthohumol: from hop plant, Humulus lupulus. xanthohumol : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4', a methoxy group at position 6' and a prenyl group at position 3'. Isolated from Humulus lupulus, it induces apoptosis in human malignant glioblastoma cells.		2.0410aromatic ether;
chalcones;
polyphenol		anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite
cardamonin
cardamonin: found in Zingiberaceae; structure in first source		2.0310chalcones
caffeic acid
trans-caffeic acid : The trans-isomer of caffeic acid.		2.0410caffeic acidgeroprotector;
mouse metabolite
5,6-dehydrokawain
5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source		2.44202-pyranones;
aromatic ether
quercetin
[no description available]		2.42207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
luteolin
[no description available]		2.25103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
butein
[no description available]		2.4820chalcones;
polyphenol		antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor
isobavachalcone
isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.		2.2510chalcones;
polyphenol		antibacterial agent;
metabolite;
platelet aggregation inhibitor
kavain
[no description available]		2.05102-pyranones;
aromatic ether
methysticin
[no description available]		2.05102-pyranones;
aromatic ether
tectochrysin
tectochrysin: structure in first source. tectochrysin : A monohydroxyflavone that is flavone substituted by a hydroxy group at position 4 and a methoxy group at position 7 respectively.		2.0310monohydroxyflavone;
monomethoxyflavone		antidiarrhoeal drug;
antineoplastic agent;
plant metabolite
4-hydroxychalcone
4-hydroxychalcone: structure in first source. 4-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4.		2.4820chalcones;
phenols		antihypertensive agent;
plant metabolite
2'-hydroxy-4-methoxychalcone
[no description available]		2.2510
5-hydroxy-3,3',4',7-tetramethoxyflavone
5-hydroxy-3,7,3',4'-tetramethoxyflavone: from the rhizome of Kaempferia parviflora; inhibits monocyte adhesion and cellular reactive oxygen species production in human umbilical vein endothelial cells. 5-hydroxy-3,3',4',7-tetramethoxyflavone : A monohydroxyflavone that is 5-hydroxyflavone which is substituted by methoxy groups at positions 3,3',4' and 7.		2103'-methoxyflavones;
monohydroxyflavone;
tetramethoxyflavone		plant metabolite
flavokawain a
flavokawain A: from kava extract, induces apoptosis in bladder cancer cells; structure in first source		3.1650chalcones
flavokawain b
flavokawain B: from Piper methysticum Forst (Kava Kava) roots; structure in first source. flavokawain B : A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities.		3.0140chalcones;
dimethoxybenzene;
phenols		anti-inflammatory agent;
antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
metabolite
Isoliquiritigenin 4,4'-dimethyl ether
[no description available]		2.2510chalcones
4-hydroxylonchocarpin
4-hydroxylonchocarpin: structure in first source		2.2510
helichrysetin
helichrysetin: isolated from Helichrysum odoratissimum; RN from CA Index Guide 1986; RN given refers to (E)-isomer; RN for cpd without isomeric designation not avail. 10/89		210chalcones
3-o-methylbutein
3-O-methylbutein: RN given refers to (E)-isomer; structure given in first source		2.110chalcones
broussochalcone a
broussochalcone A: RN given for (E)-isomer; inhibits neutrophil respiratory burst; structure in first source		2.2510
goniothalamin
goniothalamin: has antineoplastic activity; structure given in first source		2.110
panduratin a
panduratin A: isolated from Kaempferia pandurata; structure in first source		2.0310diarylheptanoidmetabolite
isopanduratin a
isopanduratin A: isolated from Kaempferia pandurata; structure in first source		2.0310
dihydrokavain
dihydrokavain: inhibits binding of batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated sodium channels		2.05102-pyranones;
aromatic ether
xanthohumol c
xanthohumol C: has antineoplastic activity; isolated from the hops of Humulus lupulus; structure in first source		2.0410chalcones
Kanzonol B
[no description available]		2.2510chalcones
5-Hydroxyauranetin
5-hydroxy-3,6,7,8,4'-pentamethoxyflavone: has diuretic activity; isolated from Rubus rosaefolius		210ether;
flavonoids
4-hydroxycoumarin
2-hydroxychromone: structure		2.110hydroxycoumarin
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Pancreas
[description not available]		02.0310
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.0310
B16 Melanoma
[description not available]		02.1110
Chronic Illness
[description not available]		02.2510
Polyarthritis
[description not available]		02.2510
Innate Inflammatory Response
[description not available]		02.2510
Arthritis
Acute or chronic inflammation of JOINTS.		02.2510
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.2510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.2510
Acute Confusional Senile Dementia
[description not available]		03.5240
Benign Neoplasms
[description not available]		03.5240
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		03.5240
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5240
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.3110
Cancer of Colon
[description not available]		02.5920
Colonic Neoplasms
Tumors or cancer of the COLON.		02.5920